Ustekinumab for the treatment of psoriatic arthritis: an update

Clin Cosmet Investig Dermatol. 2014 Sep 2;7:243-9. doi: 10.2147/CCID.S50003. eCollection 2014.


Psoriatic arthritis occurs in 30% of psoriasis patients, and the treatment can be challenging in some patients. Recently, the US Food and Drug Administration approved ustekinumab, a fully human monoclonal antibody, for the management of psoriatic arthritis. In this article, we review large-scale randomized clinical trials addressing the efficacy and safety profile of ustekinumab for the treatment of psoriatic arthritis.

Keywords: psoriasis; psoriatic arthritis; ustekinumab.

Publication types

  • Review